by CN Bio. | Oct 5, 2021 | Press releases
New Oncology Service supports unique in vitro investigations into the PK/PD relationship Harnesses CN Bio’s proprietary PhysioMimix™ PK system Represents first implementation of intellectual property licensed from Vanderbilt University to provide human-relevant...
by CN Bio. | Jul 27, 2021 | Press releases
Enables accurate modelling of the human colon and the mucosal barrier Provides new insights to the relationship between human microbiome and effect on human health Model to be integrated into CN Bio’s PhysioMimix™ OOC range of single- and multi-organ...
by CN Bio. | Jul 19, 2021 | Press releases
Lonza and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for Use on Innovative Organ-on-a-chip Range Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM...
by CN Bio. | Jun 29, 2021 | Press releases
Next generation organ-on-a-chip (OOC) technology to be used to investigate the human gut microbiome for improving outcomes for patients with liver cirrhosis Adoption follows successful collaboration demonstrating value of PhysioMimix’s ability to recapitulate...
by CN Bio. | May 5, 2021 | Press releases
The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications Extension aims to evaluate CN Bio’s PhysioMimix lung-on-a-chip platform in addition to deepening existing research collaboration for liver studies...
by CN Bio. | Mar 17, 2021 | Press releases
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS. The next-generation platform combines CN Bio’s in vitro...
